Boehringer Ingelheim International GmbH Sustainability Profile
Boehringer Ingelheim International GmbH, a leading global pharmaceutical company, is headquartered in Ingelheim am Rhein, Germany. Founded in 1885, the company has established a strong presence in the healthcare industry, focusing on human pharmaceuticals, animal health, and biopharmaceutical contract manufacturing. With a commitment to innovation, Boehringer Ingelheim is renowned for its core products, including prescription medications for respiratory diseases, cardiovascular conditions, and diabetes management. The company’s unique approach to research and development has positioned it as a key player in the market, consistently delivering groundbreaking therapies. Notable achievements include significant advancements in veterinary medicine and a robust pipeline of new treatments, reinforcing its status as one of the top pharmaceutical firms globally. Boehringer Ingelheim continues to prioritise improving patient outcomes and animal health through its dedicated efforts in scientific excellence.
DitchCarbon Score
How does Boehringer Ingelheim International GmbH's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Boehringer Ingelheim International GmbH's score of 20 is lower than 85% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Boehringer Ingelheim International GmbH, headquartered in Germany (DE), currently does not provide specific carbon emissions data for the most recent year, nor does it disclose any reduction targets or initiatives. The company is a current subsidiary of C.H. Boehringer Sohn AG & Co. KG, which may influence its climate commitments and performance metrics. As of now, there are no reported emissions figures, such as Scope 1, 2, or 3 emissions, nor any specific climate pledges or targets from the Science Based Targets initiative (SBTi). This lack of data suggests that Boehringer Ingelheim may still be in the process of establishing or reporting its carbon footprint and climate strategies. In the context of the pharmaceutical industry, companies are increasingly expected to set ambitious climate targets and report on their emissions transparently. Boehringer Ingelheim's commitment to sustainability will likely evolve as it aligns with industry standards and practices.
How Carbon Intensive is Boehringer Ingelheim International GmbH's Industry?
How Carbon Intensive is Boehringer Ingelheim International GmbH's Location?
Boehringer Ingelheim International GmbH's Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Boehringer Ingelheim International GmbH has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
